Zobrazeno 1 - 10
of 150
pro vyhledávání: '"Armin Szegedi"'
Autor:
David W. Dodick, Armin Szegedi, Peter J. Goadsby, Jessica Ailani, Kaifeng Lu, Michelle Finnegan, Joel M Trugman
Publikováno v:
The Lancet Neurology. 19:727-737
Summary Background Atogepant is an orally administered, small-molecule, calcitonin gene-related peptide (CGRP) receptor antagonist under investigation for treatment of migraine. We aimed to examine a range of oral doses for safety, tolerability, and
Autor:
Michael E. Thase, Lynn James, Mitchell F. Brin, Suresh Durgam, Jeen Liu, Armin Szegedi, Arlene Lum
Publikováno v:
International Clinical Psychopharmacology
Supplemental Digital Content is available in the text.
This 24-week double-blind placebo-controlled multicenter randomized phase 2 trial evaluated efficacy and safety of onabotulinumtoxinA (onabotA; BOTOX) vs. placebo for major depressive disord
This 24-week double-blind placebo-controlled multicenter randomized phase 2 trial evaluated efficacy and safety of onabotulinumtoxinA (onabotA; BOTOX) vs. placebo for major depressive disord
Autor:
Stewart J. Tepper, Abhijeet Jakate, Lawrence Severt, Joel M Trugman, Paul B. Watkins, Armin Szegedi, Peter J. Goadsby, Rosa Miceli, Michelle Finnegan, Girma Minalu Ayele, Matthew Butler
Publikováno v:
Cephalalgia
Background Ubrogepant is a novel, oral calcitonin gene–related peptide (CGRP) receptor antagonist in development for the acute treatment of migraine. This trial evaluated the safety and tolerability of ubrogepant, focusing on hepatic safety, when a
Autor:
David W. Dodick, Andrew M. Blumenfeld, Peter J. Goadsby, Joel M. Trugman, Michelle Finnegan, Chengcheng Liu, Susan Hutchinson, Armin Szegedi
Publikováno v:
Headache
Objective To determine the potential efficacy of ubrogepant for acute treatment of migraine based on historical experience with triptans. Background Although triptans have improved migraine treatment, their efficacy and tolerability may limit their u
Autor:
Armin Szegedi, Jessica Ailani, Michelle Finnegan, Kaifeng Lu, Joel M Trugman, Richard B. Lipton, David W. Dodick
Publikováno v:
The New England journal of medicine. 381(23)
Ubrogepant is an oral, small-molecule calcitonin gene-related peptide receptor antagonist for acute migraine treatment.We conducted a randomized trial to evaluate the efficacy, safety, and side-effect profile of ubrogepant. We assigned adults with mi
Autor:
Joel M Trugman, David W. Dodick, Armin Szegedi, Richard B. Lipton, Jessica Ailani, Michelle Finnegan, Kaifeng Lu
Publikováno v:
JAMA
Importance Ubrogepant is an oral calcitonin gene–related peptide receptor antagonist under investigation for acute treatment of migraine. Objective To evaluate the efficacy and tolerability of ubrogepant compared with placebo for acute treatment of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::20120b6b96dcffd4df7d704bef29537e
https://europepmc.org/articles/PMC6865323/
https://europepmc.org/articles/PMC6865323/
Publikováno v:
Journal of Affective Disorders. 226:326-331
Background The Hamilton Depression Rating Scale (HAM-D) and the Montgomery Asberg Depression Rating Scale (MADRS) are scales used frequently to rate the symptoms of depression. There are many situations in which it is important to know what a given t
Autor:
Xiao Wu, Maju Mathews, Armin Szegedi, Sung Yun Yu, Suresh Durgam, Mary Mackle, Ronald P. Landbloom
Publikováno v:
American Journal of Psychiatry. 175:71-79
The authors determined the efficacy and safety of asenapine in preventing recurrence of any mood episode in adults with bipolar I disorder.Adults with an acute manic or mixed episode per DSM-IV-TR criteria were enrolled in this randomized, placebo-co
Autor:
Ronald L. Landbloom, Kiki D. Chang, Qi Zhu, Mary Mackle, Sabine Braat, Robert L. Findling, Maju Mathews, Janelle Koppenhaver, Armin Szegedi
Publikováno v:
Journal of the American Academy of Child & Adolescent Psychiatry. 54(12):1032-1041
ObjectiveTo evaluate asenapine versus placebo in 403 patients aged 10 to 17 years with bipolar I disorder currently in manic or mixed episodes.MethodIn this double-blind, placebo-controlled, international trial, patients were randomized 1:1:1:1 to pl
Autor:
Armin Szegedi, Stefanie Wagner, Ralf Kohnen, André Tadić, Isabella Helmreich, Jochem König, Christoph Hiemke
Publikováno v:
Journal of Affective Disorders. 175:199-208
Background Hamilton depression rating scale (HAMD) subscales provide an economic alternative for the full scale; however, their ability to detect onset of improvement in the early course of treatment ( EI ) has not yet been researched. The present st